| 000 | 01508 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250517192639.0 | ||
| 264 | 0 | _c20181231 | |
| 008 | 201812s 0 0 eng d | ||
| 022 | _a1432-2072 | ||
| 024 | 7 |
_a10.1007/s00213-017-4813-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHenningfield, Jack E | |
| 245 | 0 | 0 |
_aThe abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. _h[electronic resource] |
| 260 |
_bPsychopharmacology _c02 2018 |
||
| 300 |
_a573-589 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAnalgesics, Opioid _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomedical Research _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aControlled Substances _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMitragyna _xchemistry |
| 650 | 0 | 4 |
_aPain _xdrug therapy |
| 650 | 0 | 4 |
_aQuality of Life _xpsychology |
| 650 | 0 | 4 |
_aSecologanin Tryptamine Alkaloids _xadministration & dosage |
| 650 | 0 | 4 |
_aSubstance Withdrawal Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aSubstance-Related Disorders _xprevention & control |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 700 | 1 | _aFant, Reginald V | |
| 700 | 1 | _aWang, Daniel W | |
| 773 | 0 |
_tPsychopharmacology _gvol. 235 _gno. 2 _gp. 573-589 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00213-017-4813-4 _zAvailable from publisher's website |
| 999 |
_c27921214 _d27921214 |
||